A proven approach to sustainable weight loss

Reduce GLP-1 spend while empowering members to lose weight with or without medications.

See published results

Skyrocketing weight loss medication costs and member demands

2–4x Costs increase for GLP-1 drug class alone

68% of GLP-1 spend is wasted due to lack of provider and lifestyle support¹

69% of members want to lose weight without medication²

Virta flexes to your organization’s weight loss strategy

Sustainable Weight Loss

Nutrition-first approach enables members to lose weight without drugs

GLP-1 alternative
GLP-1 companion

Responsible Prescribing

All-in-one GLP-1 prescribing + personalized nutrition and lifestyle support

Combo therapy
Built in off-ramp

More than just marketing claims, validated weight loss results

Only solution with a decade of experience and peer-reviewed sustained weight loss results without drugs and after GLP-1s

Years of nutrition-first care, medication management, and GLP-1 deprescription when clinically appropriate

Learn about our approach

13%

Weight loss without drugs³

View our outcomes

85%

Sustained weight loss a year after GLP-1 deprescription⁴

See the results

How it works

Easy implementation via PBM integrations

enables guardrails without rebate impact

Navigate members to Virta’s effective care

via our PBM integrations and member communications

Educate on the benefits of Nutrition Therapy

and guide each member to the right care with or without GLP-1s

Adapt nutrition and behavioral care to each member

based on lifestyle, metabolism, and continuous health data

Maximize success for those on GLP-1s

with provider-led effective titration, side-effect support, and engagement monitoring—no wasted spend on off-label prescriptions or ineffective anti-obesity medications.

Sustain results after GLP-1s

with Virta’s nutrition therapy that addresses the root cause of obesity and unhealthy weight

A proven approach for deprescribing GLP-1s when clinically appropriate

Our first of its kind research study shows sustained weight loss after deprescribing GLP-1s among a real world population.

Following GLP-1 deprescription, patients weight did not significantly increase at 6 or 12 months post deprescription, compared to many well-known drug trials (in red) where patients regain up to two thirds of weight loss after discontinuing the drug.

Line chart comparing the GLP-1 Deprescriptioon Cohort to the GLP-1 Continued Cohort.

McKenzie, A.L., Athinarayanan, S.J. Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. Diabetes Ther (2024). https://doi.org/10.1007/s13300-024-01547-0

Featured Resources

2024 Update: How Health Plan Leaders Are Handling the GLP-1 Cost Crisis [Survey Report]

Learn more

Assessing Solutions to Improve Metabolic Health

Learn more

Life-changing weight loss that lasts

** These slides will be converted to a slideshow on the live site. **

Dan lost 110 pounds and changed his attitude

“The Ozempic helped, but there is no magic bullet out there. I needed to change my diet. The energy level I have now is amazing, I’m walking 6-8 miles a day. My attitude is way better too. I didn’t care about a lot of things before, but now I do.”

Benefits leader Sheri knows Virta works first hand

“Within the first three months on Virta, all my numbers had come down and I lost 60 pounds! I can play with my grandkids now and get back up again without pain. It is incredible.“

Linda lost 65 pounds and celebrated new victories

“For decades, I had tried everything to lose weight. Bariatric surgery was next. Then I found Virta. Since then, I’ve lost 65 pounds, while reducing my medications. I can finally fit comfortably behind the steering wheel in my car and put the tray table down on an airplane. It feels like a miracle.”

Ready to learn more?

Discover how Virta is helping set a new standard in medical care for people living with obesity, type 2 diabetes, and prediabetes.

Let's talk

Citations and Footnotes

Real world analysis by Prime Therapeutics. n=4,255. Commercial data from people with obesity, prediabetes, or BMI > 30. Cited in Reuters, “Most patients using weight loss drugs like Wegovy stop within a year.” July 11, 2023
Virta Vitals: Taking America’s Pulse on Nutrition and Weight Management
McKenzie AL, Athinarayanan SJ, McCue JJ, Adams RN, Keyes M, McCarter JP, Volek JS, Phinney SD, Hallberg SJ. Type 2 Diabetes Prevention Focused on Normalization of Glycemia: A Two-Year Pilot Study. Nutrients. 2021 Feb 26;13(3):749.
McKenzie, A.L., Athinarayanan, S.J. Impact of Glucagon-Like Peptide 1 Agonist Deprescription in Type 2 Diabetes in a Real-World Setting: A Propensity Score Matched Cohort Study. Diabetes Ther (2024). https://doi.org/10.1007/s13300-024-01547-0